Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 45,506

Document Document Title
WO/2013/171345
The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and/or secondary pr...  
WO/2013/170971
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-sp iro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and ...  
WO/2013/172537
The present invention relates to a pharmaceutical composition for treating or preventing neurological disorders caused by alcohol exposure during pregnancy, and a dietary supplement for alleviating or preventing neurological disorders ca...  
WO/2013/170738
The present invention relates to an Agomelatine acid radical composite in a formula (I) and a preparation method of the composite (HX=H2S04, RSO3H (R=CH3, Ph, 4-CH3Ph)). The solubility of the Agomelatine acid radical composite obtained b...  
WO/2013/172999
The subject invention relates to compositions and methods useful for the in vivo delivery of substantially water-insoluble drugs, like taxol. The use of specific composition and preparation conditions enables the reproducible production ...  
WO/2013/172297
Provided is a solid preparation in which the elutability and stability of a 6,7-unsaturated-7-carbamoylmorphinan derivative is improved. A solid preparation or a coated solid preparation, which comprises a 6,7-unsaturated-7-carbamoylmorp...  
WO/2013/172872
The present application describes organic compounds that inhibit the activity of cytosolic heat shock protein Hsp90. Also described are methods useful for prophylaxis, treatment, or amelioration of symptoms of diseases or conditions that...  
WO/2013/171712
The present invention is concerned with novel substituted 3,4-dihydro-2H-pyrido[1,2- a]pyrazine-1,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, R5, Z and X have the meaning defined in the claims. The compounds according to t...  
WO/2013/170741
Provided are a benzodioxane compound as shown by the general formula (I), a pharmaceutical composition comprising same and the use thereof in treating psychotic and neuropathic diseases, particularly depression.  
WO/2013/172944
Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway al...  
WO/2013/168010
Compounds or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods...  
WO/2013/167403
Substituted 6-(4-Hydroxy-phenyl)-l H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula, in which R', R2 , R3, R4, R5 and R6 are defined as indicated...  
WO/2013/167985
The invention relates to the compounds of formula (I) and formula (1A) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising a...  
WO/2013/168090
The invention relates to the use of effective amount of Pelargonium graveolens essential oil or extract or constituents thereof selected from a group consisting of: (S)(-)citroneIlol, linalool, menthone and isomenthone or any combination...  
WO/2013/168627
The problem is to provide novel crystals of 5'-glucosyl adenosine the crystal structure of which has been elucidated, a 5'-glucosyl adenosine crystal-containing powder containing these crystals, the use of the same as a medical drug, and...  
WO/2013/169741
Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered loca...  
WO/2013/168131
The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer'...  
WO/2013/167112
The invention relates to a pharmaceutical composition and arrangement thereof for nasal application. The aim of the invention is to increase the efficacy of drugs, metabolites and/or other previously described types of active ingredients...  
WO/2013/167988
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/168024
Disclosed is the compounds of formula (I), formula (II), formula (la), formula (IIb) or its pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprisin...  
WO/2013/168126
Provided are crystalline and amorphous vilazodone hydrochloride. Further provided are amorphous solid dispersions of vilazodone hydrochloride with pharmaceutically acceptable carries. Also provided is a process for the preparation of for...  
WO/2013/168174
The present invention relates to methods and compositions for treating neurodegenerative conditions, such as Alzheimer's Disease, by systemic administration of specific apoE4 antibodies.  
WO/2013/167635
The present invention is related to the use of indole-dihydro-imidazole derivatives of Formula (I) as a medicament for the treatment of diseases or conditions mediated by Cdk5 and/or GSK3.  
WO/2013/168315
The purpose of the present invention is to provide a therapeutic or prophylactic agent for behavioral and psychological symptoms or dementia accompanied by behavioral and psychological symptoms, which does not cause any accessory symptom...  
WO/2013/168002
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/168003
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/170115
Disclosed are compounds of formula (IC), or a therapeutically acceptable salt thereof which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.  
WO/2013/168007
The invention relates to the compounds of formula (I), formula (II) and formula (III) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositio...  
WO/2013/167112
The invention relates to a pharmaceutical composition and arrangement thereof for nasal application. The aim of the invention is to increase the efficacy of drugs, metabolites and/or other previously described types of active ingredients...  
WO/2013/169600
The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a...  
WO/2013/167990
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/169889
The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetyl...  
WO/2013/170186
The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G,...  
WO/2013/168023
Provided are compounds, pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical,...  
WO/2013/169964
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, preventi...  
WO/2013/168014
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/168011
The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising a...  
WO/2013/167993
The invention relates to the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising a...  
WO/2013/168000
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/168021
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/168008
The invention relates to the compounds of formula (I) or its pharmaceutica! acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/167177
The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment of diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory...  
WO/2013/166654
Disclosed are compounds of Formula (I), wherein each substituent of Formula (I) is defined as in the specification, pharmaceutical formulations comprising these compounds which are useful as 0-linked N-acetylglucosaminidase (O-GlcNAcase)...  
WO/2013/168693
Provided is a method for producing sepiapterin, lactoylpterin, and tetrahydrolactoylpterin. Sepiapterin, lactoylpterin, and tetrahydrolactoylpterin are obtained at a good yield by the reaction formula.  
WO/2013/168826
The purpose of the present invention is to elucidate a regulation molecule or a target molecule for an IL-6 amplifier, and provide a method for screening for a prophylactic or therapeutic agent for diseased or disease conditions of which...  
WO/2013/166862
Provided are a diaryl[a, g]quinolizidine compound, enantiomers, diastereomeric isomers, racemates and mixtures thereof, pharmaceutically acceptable salts thereof, crystalline hydrates or solvates thereof, the preparation method therefor,...  
WO/2013/168033
Provided are compounds, pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical,...  
WO/2013/167992
The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amoun...  
WO/2013/169907
The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetyl...  
WO/2013/168019
The invention relates to the compounds of formula (I), formula (II), formula (III) and formula (IV) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceuti...  

Matches 451 - 500 out of 45,506